Emergent Biosolutions (NYSE:EBS) Director Sujata Tyagi Dayal Sells 13,761 Shares

Key Points

• Emergent Biosolutions Director Sujata Tyagi Dayal sold 13,761 shares under a pre-arranged Rule 10b5-1 plan at an average price of $8.40 for approximately $115,592, leaving her with 100,563 shares (a 12.04% reduction); the trade was disclosed in an SEC filing.
• The company reported an earnings beat—EPS of $0.21 vs. a consensus of ($0.25) and revenue of $156.1M vs. $145M—and the stock trades near $8.51 with a market cap of about $439M and a 12‑month range of $4.71–$14.06.
• Analyst coverage is mixed, with a consensus Hold rating and a $12 average target price, while institutional investors hold roughly 78.4% of the company’s shares.

Emergent Biosolutions Inc. (NYSE:EBS - Get Free Report) Director Sujata Tyagi Dayal sold 13,761 shares of the firm's stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $8.40, for a total value of $115,592.40. Following the completion of the sale, the director directly owned 100,563 shares in the company, valued at $844,729.20. This trade represents a 12.04% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Emergent Biosolutions Stock Performance

EBS traded up $0.04 during midday trading on Monday, reaching $8.51. The company's stock had a trading volume of 839,196 shares, compared to its average volume of 878,575. The stock has a market cap of $439.23 million, a P/E ratio of -30.38 and a beta of 2.33. The company has a fifty day simple moving average of $8.54 and a 200 day simple moving average of $10.30. The company has a current ratio of 4.29, a quick ratio of 2.08 and a debt-to-equity ratio of 1.10. Emergent Biosolutions Inc. has a twelve month low of $4.71 and a twelve month high of $14.06.

Emergent Biosolutions (NYSE:EBS - Get Free Report) last released its earnings results on Thursday, April 30th. The biopharmaceutical company reported $0.21 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.25) by $0.46. The firm had revenue of $156.10 million for the quarter, compared to analyst estimates of $145.00 million. Emergent Biosolutions had a positive return on equity of 10.76% and a negative net margin of 1.27%.

Wall Street Analysts Forecast Growth

EBS has been the subject of several research reports. HC Wainwright reduced their target price on shares of Emergent Biosolutions from $15.00 to $12.00 and set a "buy" rating for the company in a research note on Monday, March 9th. Wall Street Zen lowered Emergent Biosolutions from a "buy" rating to a "hold" rating in a research note on Sunday, March 8th. Finally, Weiss Ratings cut Emergent Biosolutions from a "sell (d+)" rating to a "sell (d)" rating in a report on Monday, April 27th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus target price of $12.00.

Hedge Funds Weigh In On Emergent Biosolutions

Hedge funds have recently made changes to their positions in the business. CWM LLC raised its stake in shares of Emergent Biosolutions by 5.5% in the 4th quarter. CWM LLC now owns 18,009 shares of the biopharmaceutical company's stock valued at $223,000 after buying an additional 942 shares in the last quarter. Assenagon Asset Management S.A. boosted its position in shares of Emergent Biosolutions by 2.4% during the 4th quarter. Assenagon Asset Management S.A. now owns 57,805 shares of the biopharmaceutical company's stock valued at $714,000 after acquiring an additional 1,350 shares in the last quarter. Wealth Enhancement Advisory Services LLC increased its stake in Emergent Biosolutions by 14.3% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 13,016 shares of the biopharmaceutical company's stock valued at $171,000 after acquiring an additional 1,625 shares during the period. Franklin Resources Inc. increased its stake in Emergent Biosolutions by 2.3% in the fourth quarter. Franklin Resources Inc. now owns 78,945 shares of the biopharmaceutical company's stock valued at $976,000 after acquiring an additional 1,764 shares during the period. Finally, SG Americas Securities LLC raised its position in Emergent Biosolutions by 4.6% in the first quarter. SG Americas Securities LLC now owns 42,394 shares of the biopharmaceutical company's stock worth $352,000 after purchasing an additional 1,865 shares in the last quarter. Institutional investors and hedge funds own 78.40% of the company's stock.

About Emergent Biosolutions

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company's portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent's lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.